⏳ Fetching live dividend data...
Home › Calculator › LABP Dividend Calculator 2026
Landos Biopharma, Inc. · NASDAQ
Price: $22.93 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in LABP → $23.1K in 10 years · $154.28/month
Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. Another pipeline asset, NX-13, is also an oral therapeutic localized to the gut, targeting the NOD-like receptor X1 (NLRX1) pathway, a mitochondrial receptor involved in regulating inflammatory cytokine production, for UC and CD. Furthermore, LABP-104 is an oral, small-molecule LANCL2 agonist designed to be systemically bioavailable, with potential applications in systemic lupus erythematosus and rheumatoid arthritis (RA). Beyond these clinical programs, Landos maintains a robust preclinical pipeline, featuring several promising compounds: LABP-66, an oral small molecule, acts as a NOD-like pathway agonist and is being explored for multiple sclerosis and Alzheimer's disease. LABP-69 is an oral PLXDC2 agonist targeting diabetic nephropathy and RA. LABP-73, another oral small molecule, modulates the NLRX1 pathway for potential use in asthma and chronic obstructive pulmonary disease. And LABP-111, an oral small molecule LANCL2 pathway agonist, is under investigation for nonalcoholic steatohepatitis and type 1 diabetes. Established in 2017, the company's corporate headquarters are situated in Blacksburg, Virginia.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LABP position with:
Real after-tax yield depends on where you live and how you hold LABP.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 8.72% | 5.92% | $872 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 7.41% | 4.61% | $741 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 6.98% | 4.18% | $698 / yr |
| 🇬🇧 UK ISA | 0% | 8.72% | 5.92% | $872 / yr |
| 🇬🇧 UK Taxable | 8.75% | 7.96% | 5.16% | $796 / yr |
| 🇨🇦 TFSA | 0% | 8.72% | 5.92% | $872 / yr |
| 🇨🇦 CA Taxable | 25% | 6.54% | 3.74% | $654 / yr |
| 🇦🇺 Super (pension) | 15% | 7.41% | 4.61% | $741 / yr |
| 🇦🇺 AU Taxable | 30% | 6.10% | 3.30% | $610 / yr |
| 🇩🇪 DE Taxable | 26.375% | 6.42% | 3.62% | $642 / yr |
| 🇫🇷 FR Taxable | 30% | 6.10% | 3.30% | $610 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
LABP pays quarterly — 4 times per year. Next ex-div: TBD.
How LABP compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LABP sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2024-05-23 | 1,800 | $7.90 | $14.2K | ||
| D-Return | 2024-05-23 | 1,800 | $3.30 | $5.9K | ||
| D-Return | 2024-05-23 | 1,800 | $6.40 | $11.5K | ||
| D-Return | 2024-05-23 | 1,800 | $3.30 | $5.9K | ||
| D-Return | 2024-05-23 | 1,800 | $9.10 | $16.4K | ||
| D-Return | 2024-05-23 | 1,800 | $9.10 | $16.4K | ||
| D-Return | 2024-05-23 | 1,800 | $6.40 | $11.5K | ||
| D-Return | 2024-05-23 | 1,800 | $3.30 | $5.9K | ||
| D-Return | 2024-05-23 | 3,600 | $3.05 | $11.0K | ||
| D-Return | 2024-05-23 | 1,800 | $9.10 | $16.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LABP dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Landos Biopharma, Inc. (LABP) is currently trading at $22.93, 86% below its 52-week high. The current dividend yield is 8.72% based on an annual payout of $2.00 per share.
Landos Biopharma, Inc. (LABP) is a healthcare stock currently trading at $22.93 with a dividend yield of 8.72%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →